Ferring Pharmaceuticals, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.ferringusa.com
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT00117949
- Locations
- πΊπΈ
Urology Clinics of NorthTexas, PA, Dallas, Texas, United States
πΊπΈWestern Clinical Research, Torrance, California, United States
πΊπΈUrology San Antonio Research, San Antonio, Texas, United States
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT00117286
- Locations
- πΊπΈ
Regional Urology, Shreveport, Louisiana, United States
πΊπΈLawrenceville Urology, Lawrenceville, New Jersey, United States
π¨π¦The Male and Female Health and Research Centers, Barrie, Ontario, Canada
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT00117312
- Locations
- πΊπΈ
Urology San Antonio Research, San Antonio, Texas, United States
πΊπΈSouth Orange County Medical Research Center, Laguna Woods,, California, United States
πΊπΈWestern Clinical Research, Torrance, California, United States
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 460
- Registration Number
- NCT00116753
- Locations
- πΊπΈ
SW Florida Urological Associates, Fort Myers, Florida, United States
πΊπΈRegional Urology, Shreveport, Louisiana, United States
π¨π¦The Male Health Center, Toronto, Ontario, Canada
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT00116779
- Locations
- πΊπΈ
Advanced Urology Medical Center, Anaheim, California, United States
πΊπΈPacific Clinical Research, Santa Monica, California, United States
πΊπΈSouth Florida Medical Research, Aventura, Florida, United States
Safety Study of XP12B in Women With Menorrhagia
- Conditions
- MenorrhagiaHeavy Menstrual Bleeding
- Interventions
- Drug: Tranexamic acid tablets (XP12B)
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 784
- Registration Number
- NCT00113568
- Locations
- πΊπΈ
Investigative Site, Tacoma, Washington, United States
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT00038766
- Locations
- πΊπΈ
University of Chicago, Chicago, Illinois, United States
πΊπΈWake Research Associates, Raleigh, North Carolina, United States
πΊπΈCharlotte Gastroenterology and Hepatology, PLLC, Charlotte, North Carolina, United States